These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38641791)

  • 1. Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial.
    Huang T; Hu Q; Zhou X; Yang H; Xia W; Cao F; Deng M; Teng X; Ding F; Zhong Z; Gao L; Sun J; Gong L
    BMC Infect Dis; 2024 Apr; 24(1):413. PubMed ID: 38641791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R
    Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
    Madhi SA; Koen AL; Izu A; Fairlie L; Cutland CL; Baillie V; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Aley PK; Bhikha S; Hermanus T; Horne E; Jose A; Kgagudi P; Lambe T; Masenya M; Masilela M; Mkhize N; Moultrie A; Mukendi CK; Moyo-Gwete T; Nana AJ; Nzimande A; Patel F; Rhead S; Taoushanis C; Thombrayil A; van Eck S; Voysey M; Villafana TL; Vekemans J; Gilbert SC; Pollard AJ; Moore PL; Kwatra G;
    Lancet HIV; 2021 Sep; 8(9):e568-e580. PubMed ID: 34416193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu F; Huang S; Liu X; Chen Q; Zhuang C; Zhao H; Han J; Jaen AM; Do TH; Peter JG; Dorado AG; Tirador LS; Zabat GMA; Villalobos REM; Gueco GP; Botha LLG; Iglesias Pertuz SP; Tan J; Zhu K; Quan J; Lin H; Huang Y; Jia J; Chu X; Chen J; Chen Y; Zhang T; Su Y; Li C; Ye X; Wu T; Zhang J; Xia N;
    Lancet Respir Med; 2023 Dec; 11(12):1075-1088. PubMed ID: 37979588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Goswami J; Cardona JF; Hsu DC; Simorellis AK; Wilson L; Dhar R; Tomassini JE; Wang X; Kapoor A; Collins A; Righi V; Lan L; Du J; Zhou H; Stoszek SK; Shaw CA; Reuter C; Wilson E; Miller JM; Das R;
    Lancet Infect Dis; 2024 Nov; ():. PubMed ID: 39608389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
    J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial.
    Naficy A; Kuxhausen A; Seifert H; Hastie A; Leav B; Miller J; Anteyi K; Mwakingwe-Omari A
    Hum Vaccin Immunother; 2024 Dec; 20(1):2327736. PubMed ID: 38513689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial.
    Jin P; Liu Q; Chen W; Guo X; Jiang H; Zhang R; Ding M; Zhang K; Cao Z; He J; Jia S; Wei M; Hu Y; Cui L; Wang J; Li Z; Zhang X; Xia X; Wu Y; Zhou L; Zhu Y; Gao C; Zhang T; Zhu F; Zeng G; Zhu L; Li J
    Expert Rev Vaccines; 2024; 23(1):1041-1051. PubMed ID: 39523878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.
    Thiem VD; Anh DD; Ha VH; Van Thom N; Thang TC; Mateus J; Carreño JM; Raghunandan R; Huong NM; Mercer LD; Flores J; Escarrega EA; Raskin A; Thai DH; Van Be L; Sette A; Innis BL; Krammer F; Weiskopf D
    Vaccine; 2025 Jan; 44():126542. PubMed ID: 39615342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing antibody response after COVID-19 recombinant protein vaccination in adults: A cross-sectional observational study, in Chongqing, China.
    Li J; Xu J; Liu Y; Chen L; Yu L; Xiao X; Wang Q
    Hum Vaccin Immunother; 2024 Dec; 20(1):2389602. PubMed ID: 39171541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial.
    Walsh MR; Alam MS; Pierce KK; Carmolli M; Alam M; Dickson DM; Bak DM; Afreen S; Nazib F; Golam K; Qadri F; Diehl SA; Durbin AP; Whitehead SS; Haque R; Kirkpatrick BD
    Lancet Infect Dis; 2024 Feb; 24(2):150-160. PubMed ID: 37776876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006-2010.
    Naidu L; Chiu C; Habig A; Lowbridge C; Jayasinghe S; Wang H; McIntyre P; Menzies R
    Commun Dis Intell Q Rep; 2013 Dec; 37 Suppl():S1-95. PubMed ID: 24410428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT.
    Coulton S; Nizalova O; Pellatt-Higgins T; Stevens A; Hendrie N; Marchand C; Vass R; Deluca P; Drummond C; Ferguson J; Waller G; Newbury-Birch D
    Public Health Res (Southampt); 2023 Mar; 11(3):1-77. PubMed ID: 37254608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.
    Roa CC; de Los Reyes MRA; Plennevaux E; Smolenov I; Hu B; Gao F; Ilagan H; Ambrosino D; Siber G; Clemens R; Han HH
    Hum Vaccin Immunother; 2024 Dec; 20(1):2301632. PubMed ID: 38206168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study.
    McMahon R; Toepfer S; Sattler N; Schneider M; Narciso-Abraham M; Hadl S; Hochreiter R; Kosulin K; Mader R; Zoihsl O; Wressnigg N; Dubischar K; Buerger V; Eder-Lingelbach S; Jaramillo JC
    Lancet Infect Dis; 2024 Dec; 24(12):1383-1392. PubMed ID: 39146946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice.
    Yang H; Xie Y; Li S; Bao C; Wang J; Li C; Nie J; Quan Y
    Hum Vaccin Immunother; 2024 Dec; 20(1):2364519. PubMed ID: 38880868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.
    Garrett N; Reddy T; Yende-Zuma N; Takalani A; Woeber K; Bodenstein A; Jonas P; Engelbrecht I; Jassat W; Moultrie H; Bradshaw D; Seocharan I; Odhiambo J; Khuto K; Richardson SI; Omondi MA; Nesamari R; Keeton RS; Riou C; Moyo-Gwete T; Innes C; Zwane Z; Mngadi K; Brumskine W; Naicker N; Potloane D; Badal-Faesen S; Innes S; Barnabas S; Lombaard J; Gill K; Nchabeleng M; Snyman E; Petrick F; Spooner E; Naidoo L; Kalonji D; Naicker V; Singh N; Maboa R; Mda P; Malan D; Nana A; Malahleha M; Kotze P; Allagappen JJ; Diacon AH; Kruger GM; Patel F; Moore PL; Burgers WA; Anteyi K; Leav B; Bekker LG; Gray GE; Goga A;
    PLOS Glob Public Health; 2024; 4(12):e0003260. PubMed ID: 39636838
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.